Overview

anti10a Levels in Women Treated With LMWH in the Postpartum Period

Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare between anti-10a levels in postpartum women receiving different prophylactic doses of LMWH: one group with LMWH doses adjusted by the women's weight and the second group receiving 1mg/kg to a maximum dose of 120 mg
Phase:
Phase 4
Details
Lead Sponsor:
HaEmek Medical Center, Israel
Treatments:
Enoxaparin